AMAG Pharmaceuticals Inc. (AMAG)’s Financial Results Comparing With BioSpecifics Technologies Corp. (NASDAQ:BSTC)

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) and BioSpecifics Technologies Corp. (NASDAQ:BSTC) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AMAG Pharmaceuticals Inc. 13 0.71 N/A -4.92 0.00
BioSpecifics Technologies Corp. 64 13.56 N/A 2.73 24.24

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of AMAG Pharmaceuticals Inc. and BioSpecifics Technologies Corp.


Table 2 has AMAG Pharmaceuticals Inc. and BioSpecifics Technologies Corp.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
AMAG Pharmaceuticals Inc. 0.00% -8.8% -4.3%
BioSpecifics Technologies Corp. 0.00% 0% 0%

Volatility and Risk

A 0.33 beta indicates that AMAG Pharmaceuticals Inc. is 67.00% less volatile compared to S&P 500. BioSpecifics Technologies Corp.’s 1.24 beta is the reason why it is 24.00% more volatile than S&P 500.


AMAG Pharmaceuticals Inc.’s Current Ratio is 3.2 while its Quick Ratio is 3. On the competitive side is, BioSpecifics Technologies Corp. which has a 27.1 Current Ratio and a 27.1 Quick Ratio. BioSpecifics Technologies Corp. is better positioned to pay off short and long-term obligations compared to AMAG Pharmaceuticals Inc.

Analyst Ratings

Recommendations and Ratings for AMAG Pharmaceuticals Inc. and BioSpecifics Technologies Corp. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AMAG Pharmaceuticals Inc. 0 2 0 2.00
BioSpecifics Technologies Corp. 0 0 1 3.00

AMAG Pharmaceuticals Inc. has a 46.26% upside potential and a consensus price target of $13.5. Competitively the consensus price target of BioSpecifics Technologies Corp. is $85, which is potential 37.90% upside. The data from earlier shows that analysts belief suggest that AMAG Pharmaceuticals Inc. seems more appealing than BioSpecifics Technologies Corp.

Insider & Institutional Ownership

Roughly 0% of AMAG Pharmaceuticals Inc. shares are held by institutional investors while 63.5% of BioSpecifics Technologies Corp. are owned by institutional investors. AMAG Pharmaceuticals Inc.’s share held by insiders are 2.9%. On the other hand, insiders held about 0.1% of BioSpecifics Technologies Corp.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AMAG Pharmaceuticals Inc. 3.45% -8.81% -28.41% -36.15% -50.37% -25.02%
BioSpecifics Technologies Corp. -3.75% -1.43% -2.63% 14.13% 59.21% 9.16%

For the past year AMAG Pharmaceuticals Inc. has -25.02% weaker performance while BioSpecifics Technologies Corp. has 9.16% stronger performance.


BioSpecifics Technologies Corp. beats AMAG Pharmaceuticals Inc. on 9 of the 10 factors.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has a option agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Rekynda, an investigational product designed to be an on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, and offer for sale and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.